Transparency

A Glossary of All Terms Pharma

If you’re working to control the cost of prescription drugs, you need to know the lingo used by the pharmaceutical industry. Below is a glossary of terms commonly used by players in the drug research, regulation, manufacturing, distribution, and purchasing worlds. Drug Product Terms Brand product: Branded products are not generic drugs or products. A brand can be […]

Read More
  • States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing
    State Health Policy Blog

    Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]

    Read More
  • Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation
    Publications

    As the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]

    Read More
  • An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation

    Last week, Oregon Gov. Kate Brown signed a drug cost transparency bill into law that requires drug makers to report the reasons behind dramatic drug price increases. The bill’s leading advocate and architect, state Rep. Robert Nosse, D-Portland, worked for nearly three years to create a prescription cost containment bill that would win bipartisan support […]

    Read More
  • State Legislatures Start Out Strong in 2018 with Bills to Curb Rx Drug Costs
    State Health Policy Blog

    With the federal government continuing to take no action to curb drug costs, states legislatures across the country are intensifying their efforts in 2018 to staunch the financial hemorrhage to health care budgets caused by escalating prescription drug costs. Three weeks into 2018, 43 bills designed to rein in prescription drug costs have been introduced […]

    Read More
  • State Legislative Action to Lower Pharmaceutical Costs
    Maps

    *Updated June 22, 2018* Find the status of state legislation to curb prescription drugs below. Use the category button to search for a type of legislation or click on a state to view its drug bills. Click here to view a chart listing legislation by state. Click to view state legislative action in 2017 and 2015-2016. Know about a […]

    Read More
  • Reining in Rx Drug Costs: What States Achieved in 2017 and Where They’re Heading in 2018
    State Health Policy Blog

    In a year of tense partisan debate over the future of health care, one issue has achieved rare bipartisan agreement — the need to curb rising prescription drug costs. Polls show again and again that Americans, regardless of political affiliation, view the high costs of drugs as one of their chief health care concerns. Reviews […]

    Read More
  • The National Academy of Sciences recently released a report recommending several strategies to curb prescription drug costs that attempt to strike a balance between reining in prices while fostering continued drug development and innovation. Several of the academy’s recommendations are already getting trial runs in states, which are experimenting with innovative cost-savings approaches in order […]

    Read More
  • Publications

    When states pass laws designed to control prescription drug costs, the pharmaceutical industry often responds with lawsuits claiming states are hindering interstate commerce and violating the federal Dormant Commerce Clause (DCC). NASHP’s legal experts believe states can craft drug cost policies that can withstand industry challenges. This brief by Anna Zaret and Darien Shankse provides insight and […]

    Read More
  • How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs
    State Health Policy Blog

    New state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]

    Read More